ID: ALA1627314

Max Phase: Preclinical

Molecular Formula: C24H28Cl2N4O3

Molecular Weight: 491.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc2[nH]c(C(=O)NCCC(O)CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2c1

Standard InChI:  InChI=1S/C24H28Cl2N4O3/c1-33-18-5-6-20-16(13-18)14-21(28-20)24(32)27-8-7-17(31)15-29-9-11-30(12-10-29)22-4-2-3-19(25)23(22)26/h2-6,13-14,17,28,31H,7-12,15H2,1H3,(H,27,32)

Standard InChI Key:  YRMKMEPMFOFXGH-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 491.42

Molecular Weight (Monoisotopic): 490.1538

AlogP: 3.79

#Rotatable Bonds: 8

Polar Surface Area: 80.83

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.95

CX LogP: 3.30

CX LogD: 3.17

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.45

Np Likeness Score: -1.16

References

1. Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, Luedtke RR..  (2009)  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.,  52  (8): [PMID:19331412] [10.1021/jm900095y]

2. Keck TM, John WS, Czoty PW, Nader MA, Newman AH..  (2015)  Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.,  58  (14): [PMID:25826710] [10.1021/jm501512b]

Source

Source(1):

• Scientific Literature